The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
Open accessAbstract
BACKGROUND: The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS: We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). RESULTS: The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. CONCLUSIONS: Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite 5–10% weight loss in trials, it was discontinued in 2010 after the SCOUT trial showed elevated cardiovascular events (e.g., stroke) in high-risk patients [4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the concept of treating obesity to reduce the risk of cardiovascular complications has been hampered by the lack of evidence from trials indicating that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes. 11-15”
From Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023) · cites this paper as [13]
In the citing paper
“Prospective studies that evaluated the effect of nonsurgical weight loss interventions on CV event reduction have been disappointing [4, 5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [5]
In the citing paper
“Specifically, across the obesity CVOTs, SELECT is the only study to our knowledge that only enrolled participants with established CVD, whereas in the other obesity CVOTs, 24.9% to 50.5% of participants had no prior events [5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572
S UCCESSFUL W EIGHT L OSS M AINTENANCE
Wing, R. R., & Hill, J. O. (2001) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.21.1.323 · Cited by 1,382
Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis
Dattilo, A., & Kris-Etherton, P. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/56.2.320 · Cited by 1,055
Secular Trends in Cardiovascular Disease Risk Factors According to Body Mass Index in US Adults
Gregg, E. W. (2005) · JAMA · doi:10.1001/jama.293.15.1868 · Cited by 959
Blood Pressure Lowering Treatment Trialists’ Collaboration (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1410 · Cited by 789
Flagged first, then by citations
Research works printed but not linked: 3
- 1996, Can J Cardiol, 12, 127
- 1994, Lancet, 344, 1383
- Lyznicki JM, 2001, Am Fam Physician, 63, 2185
Cited by
Sorted by citations
Items 401–500 of 943
Behary, P., Cegla, J., Tan, T., & Bloom, S. R. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1048181 · Cited by 17
Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction
Maki, K. C., Kirkpatrick, C. F., Allison, D. B., & Gadde, K. M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2209176 · Cited by 19
Morikawa, Y., Shibata, A., Okumura, N., Ikari, A., Sasajima, Y., Suenami, K., Sato, K., Takekoshi, Y., El-Kabbani, O. A. L., & Matsunaga, T. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.11.003 · Cited by 17
Research Trends of Herbal Medicines for Obesity: Mainly since 2015 to 2019
Kim, S.-J., Seo, Y., Lee, H.-S., Chang, H., Cho, J., Kim, K., & Song, M. (2020) · Journal of Korean Medicine Rehabilitation · doi:10.18325/jkmr.2020.30.4.89 · Cited by 17
Binge eating in pre-clinical models
Rospond, B., Szpigiel, J., Sadakierska−Chudy, A., & Filip, M. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.11.012 · Cited by 18
O efeito da sibutramina na perda de peso de adolescentes obesos
Franco, R. R., Cominato, L., & Damiani, D. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000002825 · Cited by 17
Lee, I., Kim, K., Kim, K., Park, J., Jeong, H.-S., Kim, Y., Na, Y., Lee, S., Ahn, K. S., Lee, J., et al. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.07.006 · Cited by 17
Wentworth, J. M., Fourlanos, S., & Colman, P. G. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.012 · Cited by 16
Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16
Xu, M., Ge, C., Qin, Y., Lou, D., Li, Q., Feng, J., Wu, Y., Hu, L., Wang, B., & Tan, J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.008 · Cited by 16
Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association
Jerkins, T. W., McGill, J. B., & Bell, D. S. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15062 · Cited by 19
Quantifying energy intake changes during obesity pharmacotherapy
Göbel, B., Sanghvi, A., & Hall, K. D. (2014) · Obesity · doi:10.1002/oby.20813 · Cited by 16
Analysis of the Drugs Withdrawn from the US Market from 1976 to 2010 for Safety Reasons
Rochelle, P. L., Lexchin, J., & Simonyan, D. (2016) · Pharmaceutical Medicine · doi:10.1007/s40290-016-0159-1 · Cited by 17
Demidova, T. Y., Volkova, E., & Gritskevich, Е. Y. (2020) · Obesity and metabolism · doi:10.14341/omet12663 · Cited by 16
Obesity pillars roundtable: Phentermine – Past, present, and future
Bays, H. E., Lazarus, E., Primack, C., & Fitch, A. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100024 · Cited by 21
Cardiovascular Safety Pharmacology of Sibutramine
Yun, J., Chung, E., Choi, K. H., Cho, D. H., Song, Y. J., Han, K. M., Cha, H.-J., Shin, J. S., Seong, W., Kim, Y., et al. (2015) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2015.033 · Cited by 16
Sibutramine promotes amygdala activity under fasting conditions in obese women
Oltmanns, K. M., Heldmann, M., Daul, S., Klose, S., Rotte, M., Schäfer, M., Heinze, H., Münte, T. F., & Lehnert, H. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2615-7 · Cited by 16
Obesity Drug Update: The Lost Decade?
Yao, F., & MacKenzie, R. G. (2010) · Pharmaceuticals · doi:10.3390/ph3123494 · Cited by 16
Mendes, D., Alves, C., & Marques, F. B. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1217989 · Cited by 16
Idzerda, N. M. A., Clegg, L. E., Hernandez, A. F., Bakris, G. L., Penland, R. C., Boulton, D. W., Bethel, M. A., Holman, R. R., & Heerspink, H. J. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13958 · Cited by 15
Cadegiani, F. A., Diniz, G. C., & Alves, G. (2017) · BMC Obesity · doi:10.1186/s40608-017-0147-3 · Cited by 15
Arya, A., Nahar, L., Khan, H. U., & Sarker, S. D. (2020) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.02.006 · Cited by 18
Drug Treatment of Obesity in Cardiovascular Disease
Charakida, M., & Finer, N. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11599000-000000000-00000 · Cited by 17
Self-citationBohula, E. A., Scirica, B. M., Fanola, C. L., Inzucchi, S. E., KEECH, A. C., McGuire, D. K., Smith, S. R., Abrahamsen, T. E., Francis, B. H., Miao, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.03.012 · Cited by 15
Kamiński, M., Miętkiewska-Dolecka, M., Kręgielska-Narożna, M., & Bogdański, P. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06971-y · Cited by 15
Block, J. P., Choudhry, N. K., Carpenter, D. P., Fischer, M. A., Brennan, T. A., Tong, A. Y., Matlin, O. S., & Shrank, W. H. (2013) · Obesity · doi:10.1002/oby.20596 · Cited by 15
Regulation of food intake and the development of anti-obesity drugs
Chen, Y. (2016) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2016.01014 · Cited by 16
Jolfaei, A. G., Lotfi, T., Pazouki, A., Meybodi, A. M., Soheilipour, F., & Jesmi, F. (2016) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.17795/ijpbs-2445 · Cited by 22
Recent Advances in Anti-Obesity Agents
Kim, M. K., & Kim, C. S. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.6.501 · Cited by 16
Cardiovascular Risk Assessment in the Development of New Drugs for Obesity
Hiatt, W. R., Goldfine, A. B., & Kaul, S. (2012) · JAMA · doi:10.1001/jama.2012.9931 · Cited by 15
Is the Way to Someone’s Heart Through Their Stomach?
Packer, M. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004551 · Cited by 15
Interventions for treating overweight or obesity in adults: an overview of systematic reviews
Figuls, M. R. I., García, L. M., Martínez‐Zapata, M. J., Pacheco, R., Mauricio, D., & Bonfill, X. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010665 · Cited by 14
RetractedTronieri, J. S., Alfaris, N., Chao, A. M., Pearl, R. L., Alamuddin, N., Bakizada, Z. M., Berkowitz, R. I., & Wadden, T. A. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.06.004 · Cited by 14
Liang, J., Shao, W., Ni, P., Liu, Q., Kong, W., Shen, W., Wang, Q., Huang, A., Zhang, G., Yang, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202403442 · Cited by 15
Shyh, G. I., & Cheng-Lai, A. (2013) · Cardiology in Review · doi:10.1097/crd.0000000000000001 · Cited by 15
Kim, K., Yang, H. J., Choi, E., Shin, M. H., Kim, K., Um, J., Lee, B.-C., & Jang, H.-J. (2013) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-013-0107-5 · Cited by 14
Bunya, N., Sawamoto, K., Uemura, S., Kyan, R., Inoue, H., Nishida, J., Kouzu, H., Kokubu, N., Miura, T., & Narimatsu, E. (2017) · Acute Medicine & Surgery · doi:10.1002/ams2.275 · Cited by 14
Klein, S., & Romijn, J. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00036-8 · Cited by 14
Management of diabetes across the course of disease: minimizing obesity-associated complications
Apovian, C. M. (2011) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s24022 · Cited by 14
Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents
Walter, C. P., Bleske, B. E., & Dorsch, M. P. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12177 · Cited by 14
Inverse Agonism at α2A Adrenoceptors Augments the Hypophagic Effect of Sibutramine in Rats
Janhunen, S. K., van der Zwaal, E. M., la Fleur, S. E., & Adan, R. A. H. (2011) · Obesity · doi:10.1038/oby.2011.51 · Cited by 14
Thermogenesis and Related Metabolic Targets in Anti-Diabetic Therapy
Arch, J. R. S. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_10 · Cited by 14
Schievink, B., Heerspink, H. J. L., Leufkens, H. G. M., de Zeeuw, D., & Hoekman, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108722 · Cited by 14
Cardiovascular Safety and Superiority of Anti-Obesity Medications
Alobaida, M., Alrumayh, A., Oguntade, A. S., Al-Amodi, F., & Bwalya, M. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s311359 · Cited by 15
Livingston, E. H., & Zylke, J. W. (2012) · JAMA · doi:10.1001/jama.2012.262 · Cited by 14
Pharmacological treatment of obesity in adults in Norway 2004–2022
Ruiz, P. L., Karlstad, Ø., Nøkleby, K., Slåtsve, K., Gulseth, H. L., Meyer, H. E., Sveen, K. A., Qvigstad, E., & Furu, K. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15515 · Cited by 14
Efeitos da sibutramina sobre o sistema reprodutor feminino de ratas Wistar
da Silva, A. C., Magalini, A. P., Santos, D. C. F. D., Malfará, W. R., & Crisci, A. R. (2018) · Revista Brasileira Multidisciplinar · doi:10.25061/2527-2675/rebram/2018.v21i1.579 · Cited by 13
Kozhuharov, V. R., Ivanov, K., Karcheva-Bahchevanska, D. P., Prissadova, N. A., & Ivanova, S. (2023) · Processes · doi:10.3390/pr11082337 · Cited by 13
The 5-HT-related gut-brain axis in obesity
Jiang, C., Zhan, Q., & Zeng, C. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123171 · Cited by 13
Chapter 2: Lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.52 · Cited by 13
Anti-obesity weight loss medications: Short-term and long-term use
Jeong, D., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120825 · Cited by 16
Derosa, G., Maffioli, P., Ferrari, I., Palumbo, I., Randazzo, S., D’Angelo, A., & Cicero, A. F. G. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01217.x · Cited by 13
Fixed-dose combination of phentermine–topiramate for the treatment of obesity
Halpern, B., Faria, A. M., & Halpern, A. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.13 · Cited by 13
Hwang, I. C., Park, J. Y., Ahn, H. Y., Kim, K. K., Suh, H. S., Ko, K. D., & Kim, K. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.11.007 · Cited by 13
Comparative Efficiency and Safety of Pharmacological Approaches to the Management of Obesity
Hainer, V. (2011) · Diabetes Care · doi:10.2337/dc11-s255 · Cited by 13
Reducing the prevalence of obesity in Canada: a call to action
Shentow-Bewsh, R., & Zuberi, D. M. (2018) · Social Work in Public Health · doi:10.1080/19371918.2018.1482252 · Cited by 13
Beyond lifestyle interventions: exploring the potential of anti‐obesity medications in the UK
Wilding, J. P. H. (2018) · Clinical Obesity · doi:10.1111/cob.12248 · Cited by 13
The future of obesity medicine: where do we go from here?
Wright, S. M., & Aronne, L. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.231 · Cited by 13
Genetic Contributors to Obesity
Sivasubramanian, R., & Malhotra, S. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.03.005 · Cited by 12
Interventions to Address Cardiovascular Risk in Obese Patients: Many Hands Make Light Work
Visco, V., Izzo, C., Bonadies, D., Feo, F. D., Caliendo, G., Loria, F., Mancusi, C., Chivasso, P., Pietro, P. D., Virtuoso, N., et al. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080327 · Cited by 14
Zomer, E., Zhou, J., Nelson, A. J., Sumithran, P., Nanayakkara, S., Ball, J., Kaye, D. M., Liew, D., Nicholls, S. J., Stub, D. A., et al. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae063 · Cited by 12
Chhabra, L., Liti, B., Kuraganti, G., Kaul, S., & Trivedi, N. (2013) · International Journal of Endocrinology · doi:10.1155/2013/856793 · Cited by 14
European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes
Jordan, J., Schlaich, M. P., Redón, J., Narkiewicz, K., Luft, F. C., Grassi, G. M., Dixon, J. B., Lambert, G. W., & Engeli, S. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283427c8b · Cited by 12
Pharmacogenetics of Obesity Drug Therapy
Guzman, A. K., Ding, M., Xie, Y., & Martin, K. A. (2014) · Current Molecular Medicine · doi:10.2174/1566524014666140811120307 · Cited by 12
Kim, K., & Park, S. W. (2012) · The Korean Journal of Obesity · doi:10.7570/kjo.2012.21.4.197 · Cited by 12
Can we win the war on obesity with pharmacotherapy?
Gotthardt, J. D., & Bello, N. T. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1232164 · Cited by 11
Jayawardena, R., Francis, T. V., Abhayaratna, S., & Ranasinghe, P. D. (2021) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-021-03450-8 · Cited by 15
Rispoli, P., Piovesan, T. S., Decorti, G., Stocco, G., & Lucafò, M. (2023) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1630 · Cited by 12
The pharmacological treatment of obesity: Past, present and future
Simonyi, G., Pados, G., Medvegy, M., & Bedros, J. R. (2012) · Orvosi Hetilap · doi:10.1556/oh.2012.29317 · Cited by 12
Zheng, M., Appel, L., Luo, F. R., Lane, R. M., Burt, D. A., Risinger, R. C., Antoni, G., Cahir, M., Keswani, S. C., Hayes, W., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3688-x · Cited by 12
Effects of Alpha-Lipoic Acid on Body Weight in Obese Subjects
Ness-Abramof, R. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.06.052 · Cited by 12
Genotoxicity of antiobesity drug orlistat and effect of caffeine intervention: an in vitro study
Chakrabarti, M., Ghosh, I., Jana, A., Ghosh, M., & Mukherjee, A. (2016) · Drug and Chemical Toxicology · doi:10.1080/01480545.2016.1236128 · Cited by 12
Morikawa, Y., Shibata, A., Sasajima, Y., Suenami, K., Sato, K., Takekoshi, Y., Endo, S., Ikari, A., & Matsunaga, T. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.009 · Cited by 12
Novel Oral Anti-Obesity Agents: New Perspectives with Lorcaserin?
Gallwitz, B. (2013) · Drugs · doi:10.1007/s40265-013-0039-x · Cited by 12
Harrington, J., Felker, G. M., Januzzi, J. L., Lam, C. S. P., Lingvay, I., Pagidipati, N. J., Sattar, N. A., Spall, H. G. C. V., Verma, S., & McGuire, D. K. (2024) · Current Cardiology Reports · doi:10.1007/s11886-023-02016-z · Cited by 11
Role of Brown Adipose Tissue in Metabolic Health and Efficacy of Drug Treatment for Obesity
Markina, N. O., Matveev, G. A., Георгиевич, З. Г., Golikova, T. I., Рыжкова, Д. В., Kononova, Y. A., Danilov, S. D., & Babenko, A. Y. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144151 · Cited by 14
Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance
Harrington, J., Gale, S. E., & Vest, A. R. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011518 · Cited by 11
Song, Q., Guo, Y., Sun, P. G., Fan, Y., & Ji, K. (2024) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202400749 · Cited by 11
Moreira, R. O., Valério, C. M., Hohl, A., Moulin, C., Moura, F., Trujilho, F. R., Gerchman, F., Corrêa, L. L., Mancini, M. C., de Melo, M. E., et al. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0422 · Cited by 18
Sibutramine: efficacy and safety of prescribing in routine clinical practice
Romantsova, T. I. (2015) · Obesity and metabolism · doi:10.14341/omet2015318-24 · Cited by 12
Kaur, K. K. (2018) · MOJ Drug Design Development & Therapy · doi:10.15406/mojddt.2018.02.00057 · Cited by 12
Povydysh, M. N., Титова, М. В., Ivkin, D. Y., Krasnova, M. V., Vasilevskaya, E. R., Fedulova, L., Ivanov, I. M., Klushin, A. G., Popova, E., & Nosov, A. M. (2023) · Nutrients · doi:10.3390/nu15030656 · Cited by 11
Stumpf, M. A. M., Cercato, C., de Melo, M. E., Santos, R. D., & Mancini, M. C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad280 · Cited by 12
Vrzal, R., Knoppová, B., Petr Bachleda, A., & Dvořák, Z. (2013) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21516 · Cited by 11
Carmody, J. S., Ahmad, N. N., Machineni, S., Lajoie, S., & Kaplan, L. M. (2015) · Endocrinology · doi:10.1210/en.2015-1226 · Cited by 11
Animal models to explore the effects of CNS drugs on food intake and energy expenditure
Vickers, S. P., & Clifton, P. G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.001 · Cited by 11
Antel, J., Albayrak, Ö., Heusch, G., Banaschewski, T., & Hebebrand, J. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0522-8 · Cited by 11
Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options
Andrew, C. A., Saunders, K. H., Shukla, A. P., & Aronne, L. J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561867 · Cited by 11
Models and Strategies in the Development of Antiobesity Drugs
Agahi, A., & Murphy, K. G. (2013) · Veterinary Pathology · doi:10.1177/0300985813492801 · Cited by 11
Idzerda, N. M. A., Stefánsson, B. V., Pena, M. J., Sjöström, C. D., Wheeler, D. C., & Heerspink, H. J. L. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz064 · Cited by 11
Anti‐obesity drugs: to be or not to be?
Dvořák, R., Sharma, A. M., & Astrup, A. V. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00828.x · Cited by 11
Self-citationObesity in primary care: prevention, management and the paradox
Haslam, D. B. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-149 · Cited by 11
Hoogwerf, B. J., Manner, D. H., Fu, H., Moscarelli, E., Gaydos, B. L., & Heine, R. J. (2016) · Diabetes Care · doi:10.2337/dcs15-3025 · Cited by 10
Lü, N., Zhang, H., Wang, Y., Wang, X., Gao, Q., Du, Y., Lei, H., & Chen, J. (2024) · Analytical Methods · doi:10.1039/d4ay00879k · Cited by 10
Haluzík, M., Mráz, M., & Svacina, S. (2014) · Drug Safety · doi:10.1007/s40264-014-0238-8 · Cited by 10
Mayer, O., Bruthans, J., Seidlerová, J., Karnosová, P., Vaněk, J., Hronová, M., Gelžinský, J., Cvíčela, M., Wohlfahrt, P., Cífková, R., et al. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.07.018 · Cited by 10
A narrative review of anti-obesity medications for obese patients with osteoarthritis
Oo, W. M., Mobasheri, A., & Hunter, D. J. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2104636 · Cited by 10
Dahlberg, S., Chang, E. T., Weiss, S. R., Dopart, P. J., Gould, E. M., & Ritchey, M. E. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s381652 · Cited by 10
Central nervous system biomarkers for antiobesity drug development
Ziauddeen, H., & Fletcher, P. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.08.015 · Cited by 10
Is there a path for approval of an antiobesity drug
Downey, M., Still, C. D., & Sharma, A. M. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32834a8726 · Cited by 10
Self-citation
Metadata
- Authors
- James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., & Renz, C. L.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- The University of Sydney (AU)
- Pontifícia Universidade Católica do Rio de Janeiro (BR)
- University College London (GB)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- Gentofte Hospital (DK)
- University of Alberta (CA)
- Abbott (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-02
- Volume
- 363
- Issue
- 10
- Pages
- 905-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2119779723
- Cited by
- 943
- References
- 33
- Citations by year
- 2026: 27 · 2025: 43 · 2024: 50 · 2023: 40 · 2022: 35 · 2021: 50 · 2020: 45 · 2019: 36 · 2018: 54 · 2017: 38 · 2016: 63 · 2015: 69 · 2014: 75 · 2013: 91 · 2012: 93
- FWCI
- 75.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- UCrea (University of Cantabria) (submittedVersion, cc-by)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- ORBi (University of Liège) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- University of Cambridge
- Eisai
- Novo Nordisk
- Shionogi
- Servier
- Allergan
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- sibutramine, cardiovascular outcomes, obesity, overweight, weight management, cardiovascular risk, myocardial infarction, stroke, cardiovascular mortality, type 2 diabetes, blood pressure, weight loss, older adults, drug safety, appetite suppressants, anti-obesity drugs, cardiovascular events, cardiovascular risk reduction, cardiovascular risk stratification
- MeSH terms
- Aged, Appetite Depressants, Blood Pressure, Cardiovascular Diseases, Cyclobutanes, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Obesity, Stroke, Overweight, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
